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Introduction: Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s syndrome (SjS) are
inflammatory systemic autoimmune diseases (SADs) that share several clinical and pathological features. The shared
biological mechanisms are not yet fully characterized. The objective of this study was to perform a meta-analysis
using publicly available gene expression data about the three diseases to identify shared gene expression signatures
and overlapping biological processes.
Methods: Previously reported gene expression datasets were selected and downloaded from the Gene Expression
Omnibus database. Normalization and initial preprocessing were performed using the statistical programming
language R and random effects model–based meta-analysis was carried out using INMEX software. Functional
analysis of over- and underexpressed genes was done using the GeneCodis tool.
Results: The gene expression meta-analysis revealed a SAD signature composed of 371 differentially expressed
genes in patients and healthy controls, 187 of which were underexpressed and 184 overexpressed. Many of these
genes have previously been reported as significant biomarkers for individual diseases, but others provide new clues
to the shared pathological state. Functional analysis showed that overexpressed genes were involved mainly in
immune and inflammatory responses, mitotic cell cycles, cytokine-mediated signaling pathways, apoptotic processes,
type I interferon–mediated signaling pathways and responses to viruses. Underexpressed genes were involved primarily
in inhibition of protein synthesis.
Conclusions: We define a common gene expression signature for SLE, RA and SjS. The analysis of this signature
revealed relevant biological processes that may play important roles in the shared development of these pathologies.Introduction
Autoimmunity refers to the failure of the immune system
to recognize its own constituent parts, eliciting an im-
mune response against the tissues themselves. Currently,
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article, unless otherwise stated.diseases [1], and the biological mechanisms that cause
them are not clearly understood. It has been suggested
that both genetic and environmental factors influence
the development of autoimmune diseases [2]. Three of
these inflammatory, autoimmune diseases are systemic
lupus erythematosus (SLE), rheumatoid arthritis (RA) and
Sjögren’s syndrome (SjS).
Although at first appearance these disorders have dif-
ferent phenotypes, they all are heterogeneous, multifac-
torial disorders that share molecular mechanisms which
elicit similar clinical and pathogenic features. In fact, a
differential diagnosis between these immune disorders at
an early stage is not always reliable, and treatments are
similar for all three, except when organ damage ensuesd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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Toro-Domínguez et al. Arthritis Research & Therapy    Page 2 of 8or features of one dominate over another. Therefore,
one of the major aims in this field is to discover simila-
rities and differences at the molecular level between
these diseases and between groups of patients across
diseases. This will lead to a better understanding of the
specific biological mechanisms and the development of
more efficient and personalized treatments.
In this context, the analysis of gene expression pat-
terns can provide useful information for understanding
the molecular mechanisms by defining specific gene
expression signatures that underlie these disorders.
These studies are becoming more plentiful as a result of
the development of high-throughput technologies such
as microarrays and next-generation sequencing. These
methods allow us to measure gene expression on a
genome-wide scale, including for autoimmune diseases,
and have been widely used during the past decade (see,
for example, [3-5]). In this field, meta-analysis tech-
niques offer the potential to integrate and jointly analyze
data from different sources. In previous meta-analyses,
investigators have combined data related to the same
disease from different studies to get more consistent
and reliable results. For example, Song et al. [6] per-
formed a meta-analysis integrating three public SjS
datasets. Arasappan et al. [7] conducted a pathway-based
meta-analysis of four SLE datasets and identified a
37-gene signature associated with this disease. Olsen et al.
[8,9] analyzed different RA datasets and found several
genes related to pathways such as type I interferon (IFN),
apoptotic processes and cell cycles.
Moreover, meta-analytic techniques have also been used
to integrate data from different diseases to uncover similar
patterns. In this context, Tuller et al. [4] analyzed public
data on six different autoimmune diseases (multiple
sclerosis, SLE, juvenile RA, Crohn’s disease, ulcerative
colitis and type 1 diabetes) from peripheral blood mo-
nonuclear cells (PBMCs). Silva et al. [10] combined SLE
and RA data to uncover coexpression patterns, and Higgs
et al. [11,12] integrated data on SLE, myositis, RA and
scleroderma and defined a common type I IFN-related
signature.
In this study, we performed a gene expression meta-
analysis using publicly available gene expression data
from PBMC samples of SLE, RA and SjS patients and
controls. To the best of our knowledge, this is the first
study in which gene expression data from these three
diseases have been integrated, together with analysis of
the common gene expression signatures with respect to
healthy controls.
Methods
Search and selection of datasets
We mined the National Center for Biotechnology Informa-
tion (NCBI) Gene Expression Omnibus (GEO) database[13] to find all publicly available gene expression datasets
related to SLE, RA and SjS. From among all published
studies, we selected for our analysis those that fit the fol-
lowing criteria: (1) They had to include control and case
samples in separate arrays (one-channel arrays); (2) they
had to have been performed with human PBMC samples;
and (3) the samples had to have been obtained without any
type of treatment.
Processing of the datasets and meta-analysis
Initial processing of the data was carried out using the
R statistical programming language. Each dataset was
downloaded from the NCBI GEO database using the
GEOquery R package [14], and probes were annotated
with the Entrez Gene identifiers, which were used to
merge data from different platforms for further analysis.
In each dataset, gene expression profiles were averaged
for duplicate genes by computing the median values.
Genes with missing values in more than 10% of samples
were filtered out, and the remaining missing values were
imputed using the average expression values within the
group (case or control). The integration of different
datasets and gene expression meta-analysis was per-
formed using the INMEX software package [15]. Gene
expression values were log-transformed and normalized
by applying quantile normalization. The dataset for iden-
tification of genes specifically overexpressed in lupus
CD4 T and B cells [GEO:GSE4588] contains samples
from SLE and RA patients; therefore, these two sub-
populations were treated as two different datasets.
Differential expression meta-analysis across diseases
and healthy controls was carried out by using a random
effects model (REM) [16,17], which is based on combin-
ing the effect sizes (ESs) or changes of gene expression
from different studies and obtaining an overall mean.
Functional analysis
In order to obtain biological information from the list of
differentially expressed genes, we performed a functional
analysis using the GeneCodis tool [18-21]. This software
allows evaluation of which annotations are significantly
enriched in a gene list, which can be used as functional
descriptors of the biological processes that are acting in
experimental conditions [19,20]. Gene Ontology (GO)
and Kyoto Encyclopedia of Genes and Genomes pathway
annotations were evaluated in the analysis.
Results
Studies selected for the meta-analysis
After conducting a thorough search, we identified 19
datasets related to SLE, RA and SjS. From among this
initial set, we dismissed three datasets that included
treated samples, four datasets without control samples,
five with too many missing values (more than 50% of
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arrays. Thus, our final meta-analysis included four data-
sets (Table 1). The selected datasets comprise a total of
371 samples with a breakdown of 94 controls, 190 SjS
samples, 54 SLE samples and 33 RA samples.
Identifying a common gene expression signature among
systemic lupus erythematosus, rheumatoid arthritis and
Sjögren’s syndrome
For meta-analysis, the processed data were loaded into
the INMEX web tool, and ES statistical analysis was
used to find genes that were differentially expressed
among diseases and healthy controls across different
studies. Rather than requiring us to merge the original
datasets, this method allowed us to combine them
through high-level summary statistics, thus avoiding the
problem of interstudy variation.
We identified 412 genes that were consistently dif-
ferentially expressed (P < 0.05). Among the different
studies (see Additional file 1), 210 genes were overex-
pressed and 202 were underexpressed.
Among this initial set, we found 187 overexpressed
genes in all diseases with respect to healthy controls and
184 that were underexpressed. Additional file 1 gives the
average fold changes of each gene in all datasets. This set
comprises the common gene expression signature—that
is, genes that are significantly differentially expressed in all
diseases with respect to healthy controls. Figure 1 shows
the top 50 over- and underexpressed genes.
Some of the most differentially expressed genes were
HERC6, which belongs to the HERC family of E3 ubiqui-
tin ligases, and RTP4, which encodes a receptor (chemo-
sensory) transporter protein related to “chemotaxis” and
was previously described as an IFN-inducible gene [25].
In addition, the most overexpressed genes with the lar-
gest ESs were RSAD2 and IFI44L. IFI44L encodes the
IFN-induced protein 44-like, which has been described
in several autoimmune diseases in conjunction with
other genes involved in the type I IFN signaling pathway,
such as IFIT1, IFI27 and IFITM1. We also found overex-
pression of these genes in our results.
The gene with the lowest ES (ES = −1.2545) was eukar-
yotic translation elongation factor 2 (EEF2), a biomarker
protein of some types of cancer [26] that plays an im-
portant role in protein synthesis. This was, in fact, the
most relevant pathway that was associated with under-
expressed genes.
Meta-analytic techniques have been also used to eva-
luate reproducibility and bias across microarray studies.
This is especially important when comparing replicated
samples or samples of the same condition or phenotype.
In this sense, there are different methods that can be
used for this purpose [27]. In this context, we also eva-
luated the meta-analysis results with those obtainedfrom individual analyses of studies and/or diseases. We
found 132 gained genes and 2,168 lost genes in our
meta-analysis (see Additional file 1). Gained genes are
the differentially expressed genes identified only in the
meta-analysis and not in the individual analysis, because
they show weak signals but consistent expression pat-
terns across the different datasets. Lost genes are genes
identified as differentially expressed genes in any indivi-
dual analysis, but not in the meta-analysis. These genes
show either conflicting changes in expression profiles
or very large variations across different studies [6,15].
Additional file 2 contains a detailed study of the diffe-
rent datasets and the analysis used in our study.Functional and pathway analysis
For the analysis of biological processes associated with the
differentially expressed genes, we evaluated the enrich-
ment of functional annotations using the GeneCodis tool
[18]. GO annotations for biological processes were sig-
nificantly overrepresented in the gene list if they showed a
P-value <0.05. Results for biological pathways of overex-
pressed and underexpressed genes are shown in Figure 2
and Additional file 1. Functions such as “mitotic cell
cycle,” “cytokine-mediated signaling pathway,” “response
to virus” or “type I IFN-mediated signaling pathway” or
“immune response” were significantly associated with this
set of genes. This is in agreement with previous work
that has associated these pathways with each of the dis-
eases [12,28-31].
Similarly, the most significant GO categories or path-
ways in the analysis of underexpressed genes were “gene
expression” and others related to protein biosynthesis
mechanisms previously reported [32].Discussion
In this study, we define a signature of differentially ex-
pressed genes for SLE, RA and SjS using a gene expression
meta-analytic strategy showing common biological mech-
anisms across three otherwise clinically separate entities.
The combined ES and REM meta-analytic method was
chosen because it allowed us to integrate microarray data-
sets from different platforms consistently, without the
obstacle of the batch effects that we clearly observed when
we began our analyses. We performed the meta-analysis
using four publicly available datasets and defined a com-
mon signature composed of 187 overexpressed genes and
184 underexpressed genes in all diseases compared to
healthy controls. We found significant pathways related to
overexpressed genes, such as “immune response,” “type I
IFN-mediated signaling pathway,” “cytokine-mediated sig-
naling pathway,” “mitotic cycle” and “response to virus,”
as well as pathways related to underexpressed genes that
highlight gene expression and metabolic processes.
Table 1 Datasets used in the studya
GEO ID Platform Disease Cases/controls Description Reference Key findings
[GEO:GSE10325] Affymetrix Human Genome
U133A Array
SLE 39/28 Expression data from
human peripheral blood
subsets
[22] Some apoptotic genes are related to SLE phenotype
[GEO:GSE15573] Affymetrix Human Genome
U133 Plus 2.0 Array
RA 18/15 Immunity and defense
genes in PBMCs of RA
patients
[23] 283 underexpressed genes (involved in metabolic processes),
101 overexpressed (immunity, calcium transport)
[GEO:GSE4588] Illumina Human 6 v2.0
expression BeadChip
SLE, RA 15 SLE, 15 RA/19 Identification of genes
specifically overexpressed
in SLE CD4 T and B cells
– –
[GEO:GSE51092] Illumina Human WG-6 v3.0
expression BeadChip
SjS 190/32 Variants at multiple loci




[24] Risk loci for SjS (related to IFN pathway, STATs,
chemokine receptors, interleukins proteins or a BLK
aNCBI GEO ID: Unique gene expression series identifier for each dataset in the National Center for Biotechnology Information Gene Expression Omnibus database; Platform: Microarray platform; Disease: Type of disease
and number of cases/controls in each dataset; Description: Brief description of the study; Reference: Publication; Key findings: Main findings in the original studies. BLK, B Lymphocyte Kinase Protein; IFN, Interferon;















Figure 1 Heatmap of top differentially expressed genes. The heatmap represents the log2- transformed expression values with the top 50
overexpressed (top) and top 50 underexpressed (below) genes.
Toro-Domínguez et al. Arthritis Research & Therapy    Page 5 of 8In this context, independent studies of SLE, RA and/or
SjS have shown that overexpression of type I IFN-related
genes is very consistent [28-31,33,34], and it appears that
these genes roughly form a common pattern in all inflam-
matory autoimmune diseases [4,6,7,9-12]. The cytokine
signaling pathway-related genes behave similarly. In fact,
both routes are tightly related. IFN proteins regulate
several signaling pathways normally in response to patho-
gens, such as apoptosis or immune stimulation. In the
gene expression signature, we identified several type I
IFN-related genes as the most significantly overexpressed
genes in all diseases, such as IFI44L, IFI44, IFI27 and
IFIT1. We also found other genes, such as JAK2, involved
in the Janus kinase/signal transducer and activator of tran-
scription (JAK/STAT) signaling pathway and previously
related to immune disorders [35]. JAK/STAT signaling
promotes IFN-stimulated gene transcription. OASL is and
IFN-inducible protein related to antiviral activity [36]. In
addition, we found genes related to apoptosis, with genes
such as FAS, which has been described as a risk allele in
some autoimmune diseases [37,38]; TNFSF10; and CASP1.
We also identified several proteasome subunits, such as
PSM2, PSM6 and PSMC2. Apoptotic processes have been
related to autoimmune diseases in different studies [39].
Apoptotic cells are not immunologically neutral, and
the accumulation of apoptotic material not properlyphagocytosed can be an important source of autoimmune
antigens, enabling the development of autoimmune disor-
ders [40]. In this context, there are some hypotheses
focused on the increase in apoptosis, lazy phagocytes or
the interaction between apoptotic material and antigen-
presenting cells as potential triggers for these diseases.
In addition, some of these genes have been described
previously as biomarkers of one or a variety of auto-
immune diseases, such as IFN-induced protein 44-like,
chemokine receptor 1 and FAS. Therefore, our results
are consistent with previously published data for each of
the three disorders, but show, for the first time to our
knowledge, and formally, their shared genetic signatures.
Moreover, we found interesting results, such as the
overexpression of EIF2AK2 gene (or PKR) (see Additional
file 1). This gene is initially related to the response to virus
and the innate immune response and encodes a serine/
threonine protein kinase that is activated by autophospho-
rylation after binding to double-stranded RNA [41]. The
activated form can phosphorylate multiple substrates, in-
cluding several translation initiation factors, such as
eIF2A, eIF3F eIF2S1 and eEF2, impairing the recycling of
these factors between successive rounds of initiation and
leading to inhibition of translation, which eventually re-
sults in shutdown of cellular protein synthesis and a re-
duction in cell proliferation [42,43]. This is in agreement
Figure 2 Biological function related to the differentially expressed genes. This graphic shows the main Gene Ontology (GO) biological
functions identified and related to overexpressed genes (A) and underexpressed genes (B). GO annotations were considered significantly
enriched in the list of genes if they had a P-value <0.01 and were associated with at least ten genes. The x-axis represents the number of genes,
and the y-axis shows the names of the significant GO categories sorted by decreasing P-values.
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bition of gene expression and protein synthesis in the list
of underexpressed genes.
In a previous study of SLE, Groulleau et al. [32] de-
scribed the relationship between PKR and the phospho-
rylation of the eIF2A translation initiation factor, but
this action was attributed only to SLE, whereas re-
searchers in other studies independently related PKR
with RA [44,45]. In addition, PKR phosphorylates p38,
JNK and nuclear factor κB (NF-κB), which are proteins
of the mitogen-activated protein kinase signaling path-
way related to the production of cytokines and tumor
necrosis factor [46]. These in turn intervene in apoptotic
processes, regulation of signal transduction or cell pro-
liferation and differentiation. PKR has direct influences
on the production of IFNs [47,48]. We also found other
genes related to the immune system, such as MYD88,
which is an adaptor protein of Toll-like receptors that
activates NF-κB and translocates to the nucleus tostimulate the expression of certain genes for the produc-
tion of cytokines and IFN proteins [49].
Regarding the pathways related to underexpressed genes,
the two most relevant processes were “gene expression”
and “cellular protein metabolic process”. Analysis of genes
associated with these annotations revealed that many were
genes involved in translation, such as ribosomal protein-
encoding genes, and different eukaryotic translation ini-
tiation factor subunits, such as eEF2 or eIF3F mentioned
above. The relationship between the underexpression of
these genes and autoimmune disease is largely undefined.
We also found genes involved in translation and cell
growth, which are underexpressed, as mentioned above.
Conclusions
We performed a gene expression meta-analysis using
previously published datasets obtained from PBMCs of
SLE, RA and SjS patients. A common gene expression
signature was defined, comprising many genes that have
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diseases. Although there are previous gene expression
meta-analyses of immune-related diseases, our present
study is the first one, to our knowledge, in which data
on these three specific disorders have been integrated,
which allowed us to define common biological pro-
cesses. We found that pathways in our results, such as
“type I IFN-mediated signaling pathway,” apoptotic pro-
cesses, “immune response,” reduction in translation pro-
cesses and “response to virus.” This suggests that a
majority of these pathways are related to the action of
the IFN proteins. However, we found other pathways,
such as mitotic cell cycles, whose relationship to the IFN
pathway, or even to the diseases themselves, has not
been described. Future functional and specific studies of
the genes we identified are needed to define the roles of
these genes in the pathogenesis of SADs.Additional files
Additional file 1: Four Excel spreadsheets with results from the
meta-analysis. Spreadsheet 1: Differential gene expression analysis
results with list of the names of the genes and their Entrez ID, the value
of the combined ESs among the different experiments for each gene and
the associated P-values. The left column shows the upexpressed genes,
and the right column shows the underexpressed genes. Spreadsheet 2:
The fold changes of each gene in all datasets. Genes marked with an
asterisk were removed from the gene expression signature, as they did
not show a consistent pattern of overexpression or underexpression in all
diseases. Spreadsheet 3: Gain and loss gene lists. Spreadsheet 4: All GO
categories enriched in the gene signature are listed, with the minimum
number of genes set to three. The table contains the number of genes in
each pathway, the corrected P-values (Hyp*), the GO annotation numbers
and the names of the pathways and the genes related to each pathway.
Additional file 2: Detailed study of the different datasets used and
their influence in the final results of the meta-analysis.Abbreviations
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